Annual report pursuant to Section 13 and 15(d)

Corporate Information - Narrative (Details)

v3.21.1
Corporate Information - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Mar. 29, 2021
Mar. 24, 2021
Mar. 31, 2021
Nov. 30, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2014
Subsequent Event [Line Items]              
Cash and cash equivalents         $ 70,436 $ 62,260  
Revenues         29,323 46,279  
Net loss         (37,230) (25,469)  
Accumulated deficit         (211,406) (174,176)  
Private Placement              
Subsequent Event [Line Items]              
Net proceeds from underwritten public offering       $ 31,000      
Seagen              
Subsequent Event [Line Items]              
Revenues         9,702 2,493  
Seagen | Subsequent Event | Private Placement              
Subsequent Event [Line Items]              
Net proceeds from underwritten public offering   $ 13,000 $ 13,000        
AstraZeneca              
Subsequent Event [Line Items]              
Revenues         $ 8,308 $ 25,828  
AstraZeneca | Subsequent Event              
Subsequent Event [Line Items]              
Revenues     13,000        
AstraZeneca | Subsequent Event | Private Placement              
Subsequent Event [Line Items]              
Net proceeds from underwritten public offering $ 10,000   $ 10,000        
Pieris Pharmaceuticals GmbH              
Subsequent Event [Line Items]              
Ownership interest acquired (as a percent)             100.00%